Andrew R. Allen

4.6k total citations
49 papers, 964 citations indexed

About

Andrew R. Allen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Andrew R. Allen has authored 49 papers receiving a total of 964 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Andrew R. Allen's work include Lung Cancer Treatments and Mutations (10 papers), PARP inhibition in cancer therapy (9 papers) and Fibroblast Growth Factor Research (7 papers). Andrew R. Allen is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), PARP inhibition in cancer therapy (9 papers) and Fibroblast Growth Factor Research (7 papers). Andrew R. Allen collaborates with scholars based in United States, United Kingdom and France. Andrew R. Allen's co-authors include Charles D. Pusey, G. Gaskin, Lindsey Rolfe, Jennifer Smith, Sarah Jaw‐Tsai, Dorian O. Haskard, Roy R. Lobb, Jean‐Charles Soria, D. Ross Camidge and Jonathan W. Goldman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Andrew R. Allen

49 papers receiving 936 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew R. Allen United States 16 392 372 361 131 123 49 964
David Nicol Australia 23 506 1.3× 636 1.7× 455 1.3× 128 1.0× 296 2.4× 65 1.5k
N. L. Fox United States 17 249 0.6× 533 1.4× 249 0.7× 341 2.6× 149 1.2× 36 1.5k
Stacey DaCosta Byfield United States 13 213 0.5× 753 2.0× 579 1.6× 101 0.8× 245 2.0× 51 1.5k
Berna C. Özdemir Switzerland 14 249 0.6× 496 1.3× 436 1.2× 142 1.1× 248 2.0× 47 1.2k
Yuko Hashimoto Japan 19 221 0.6× 184 0.5× 517 1.4× 180 1.4× 75 0.6× 114 1.3k
Jennifer Tseng United States 13 205 0.5× 326 0.9× 331 0.9× 82 0.6× 157 1.3× 23 796
Savita Dandapani United States 13 129 0.3× 419 1.1× 369 1.0× 49 0.4× 110 0.9× 62 905
Kilian M. Gust Austria 26 421 1.1× 485 1.3× 544 1.5× 96 0.7× 210 1.7× 93 1.8k
Hiroshi Moritake Japan 17 119 0.3× 301 0.8× 181 0.5× 99 0.8× 78 0.6× 80 874
Stefan Hinz Germany 25 767 2.0× 830 2.2× 401 1.1× 89 0.7× 317 2.6× 98 1.9k

Countries citing papers authored by Andrew R. Allen

Since Specialization
Citations

This map shows the geographic impact of Andrew R. Allen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew R. Allen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew R. Allen more than expected).

Fields of papers citing papers by Andrew R. Allen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew R. Allen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew R. Allen. The network helps show where Andrew R. Allen may publish in the future.

Co-authorship network of co-authors of Andrew R. Allen

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew R. Allen. A scholar is included among the top collaborators of Andrew R. Allen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew R. Allen. Andrew R. Allen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hecht, J. Randolph, Alexander I. Spira, Anthony V. Nguyen, et al.. (2025). A randomized phase 2 study of an individualized neoantigen-targeting immunotherapy in patients with newly diagnosed metastatic microsatellite stable colorectal cancer (MSS-CRC).. Journal of Clinical Oncology. 43(4_suppl). 3 indexed citations
2.
Kubzansky, Laura D., Julia K. Boehm, Andrew R. Allen, et al.. (2020). Optimism and risk of incident hypertension: a target for primordial prevention. Epidemiology and Psychiatric Sciences. 29. e157–e157. 22 indexed citations
3.
Abu‐Khalaf, Maysa, Ingrid A. Mayer, Andrew R. Allen, et al.. (2015). A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer.. Journal of Clinical Oncology. 33. 2 indexed citations
4.
Domchek, Susan M., Robert R. McWilliams, Andrew Hendifar, et al.. (2015). Abstract B102: A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation. Cancer Research. 75(13_Supplement). B102–B102. 3 indexed citations
5.
Haringsma, Henry J., Andrew R. Allen, Thomas C. Harding, & Andrew D. Simmons. (2015). Abstract 3595: In vivo acquired resistance to the mutant EGFR inhibitor Rociletinib (CO-1686) is associated with activation of the c-MET pathway. Cancer Research. 75(15_Supplement). 3595–3595. 2 indexed citations
6.
Soria, J.C., Filippo de Braud, Rastilav Bahleda, et al.. (2014). Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Annals of Oncology. 25(11). 2244–2251. 147 indexed citations
7.
8.
Spigel, David R., Jason B. Litten, Andrew R. Allen, et al.. (2014). A single arm, open-label, phase II study to assess the efficacy of lucitanib in patients with FGFR1-amplified squamous NSCLC (sqNSCLC).. Journal of Clinical Oncology. 32(15_suppl). TPS8119–TPS8119. 4 indexed citations
9.
Walter, Annette O., Henry J. Haringsma, Kevin Lin, et al.. (2011). Abstract C189: CO-1686, an orally available, mutant-selective inhibitor of the epidermal growth factor receptor (EGFR), causes tumor shrinkage in non-small cell lung cancer (NSCLC) with T790M mutations.. Molecular Cancer Therapeutics. 10(11_Supplement). C189–C189. 11 indexed citations
10.
Williamson, Stephen K., Chung-Tsen Hsueh, Andrew R. Allen, et al.. (2008). PDGFR inhibition using imatinib (I) combined with docetaxel (D), a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer (NSCLC): Preliminary efficacy results. Journal of Clinical Oncology. 26(15_suppl). 19055–19055. 1 indexed citations
11.
Allen, Andrew R.. (2007). Epigenetic alterations and cancer: new targets for therapy.. PubMed. 10(10). 709–12. 5 indexed citations
12.
Adkins, Rodney H., Chad K. Klauser, John N. Fain, et al.. (2005). Abstracts from the Fourteenth Annual Meeting of the International Genetic Epidemiology Society. Genetic Epidemiology. 29(3). 234–298. 1 indexed citations
13.
Bast, Robert C., Hans Lilja, Nicole Urban, et al.. (2005). Translational Crossroads for Biomarkers. Clinical Cancer Research. 11(17). 6103–6108. 63 indexed citations
14.
Browne, Gemma, Paul A. Brown, Charles Tomson, et al.. (2004). Retransplantation in Alport post-transplant anti-GBM disease. Kidney International. 65(2). 675–681. 34 indexed citations
15.
Niehaus, Dana, et al.. (2002). Attitudes towards and beliefs about schizophrenia in Xhosa families with affected probands. Curationis. 25(1). 69–73. 40 indexed citations
16.
17.
Allen, Andrew R., Julie McHale, Jennifer Smith, et al.. (1999). Endothelial Expression of VCAM-1 in Experimental Crescentic Nephritis and Effect of Antibodies to Very Late Antigen-4 or VCAM-1 on Glomerular Injury. The Journal of Immunology. 162(9). 5519–5527. 37 indexed citations
18.
Allen, Andrew R., Julie McHale, Jennifer Smith, et al.. (1999). Endothelial expression of VCAM-1 in experimental crescentic nephritis and effect of antibodies to very late antigen-4 or VCAM-1 on glomerular injury.. PubMed. 162(9). 5519–27. 40 indexed citations
19.
Allen, Andrew R., Charles D. Pusey, & G. Gaskin. (1998). Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis.. Journal of the American Society of Nephrology. 9(7). 1258–1263. 83 indexed citations
20.
Allen, Andrew R., et al.. (1997). Enteric hyperoxaluria and renal failure associated with lymphangiectasia. Nephrology Dialysis Transplantation. 12(4). 802–806. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Nicol Breakdown of academic impact, for papers by N. L. Fox Breakdown of academic impact, for papers by Stacey DaCosta Byfield Breakdown of academic impact, for papers by Berna C. Özdemir Breakdown of academic impact, for papers by Yuko Hashimoto Breakdown of academic impact, for papers by Jennifer Tseng Breakdown of academic impact, for papers by Savita Dandapani Breakdown of academic impact, for papers by Kilian M. Gust Breakdown of academic impact, for papers by Hiroshi Moritake Breakdown of academic impact, for papers by Stefan Hinz
Rankless by CCL
2026